EDGAR Filing Documents for 0001144204-17-017762

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:

SEC Accession No. 0001144204-17-017762

Filing Date

2017-03-30

Accepted

2017-03-30 17:20:27

Documents

Period of Report

2016-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 20-F	v463022_20f.htm	20-F	1479485
2	EXHIBIT 23.1	v463022_ex23-1.htm	EX-23.1	2406
3	EXHIBIT 23.2	v463022_ex23-2.htm	EX-23.2	2778
4	EXHIBIT 31.1	v463022_ex31-1.htm	EX-31.1	11104
5	EXHIBIT 31.2	v463022_ex31-2.htm	EX-31.2	11034
6	EXHIBIT 32.1	v463022_ex32-1.htm	EX-32.1	4867
7	GRAPHIC	pg31img1_20f.jpg	GRAPHIC	35491
8	GRAPHIC	pg97img1_20f.jpg	GRAPHIC	4158
	Complete submission text file	0001144204-17-017762.txt		1567574

Mailing Address 5 HACHAROSHET ST. RAANANA L3 4365603

Business Address XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE NEW YORK NY 10016 972 9 955 7080

XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3
Type: 20-F | Act: 34 | File No.: 001-36000 | Film No.: 17726930
SIC: 2834 Pharmaceutical Preparations